The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
Blood biomarkers for Alzheimer's disease in clinical practice and trials
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
Performance of plasma phosphorylated tau 181 and 217 in the community
Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both
amyloid and tau pathology in clinical settings, but their performance in heterogeneous …
amyloid and tau pathology in clinical settings, but their performance in heterogeneous …
Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape
Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ …
MJ Pontecorvo, M Lu, SC Burnham, AE Schade… - JAMA …, 2022 - jamanetwork.com
Importance Plasma biomarkers of Alzheimer disease may be useful as minimally invasive
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of …
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of …
Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years
J Simrén, U Andreasson, J Gobom… - Brain …, 2022 - academic.oup.com
The recent development of assays that accurately quantify neurofilament light, a neuronal
cytoskeleton protein, in plasma has generated a vast literature supporting that it is a …
cytoskeleton protein, in plasma has generated a vast literature supporting that it is a …
Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light
Background and Objectives To evaluate whether plasma biomarkers of amyloid
(Aβ42/Aβ40), tau (p-tau181 and p-tau231), and neuroaxonal injury (neurofilament light …
(Aβ42/Aβ40), tau (p-tau181 and p-tau231), and neuroaxonal injury (neurofilament light …
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
A Pichet Binette, S Janelidze, N Cullen… - Alzheimer's & …, 2023 - Wiley Online Library
Introduction Plasma biomarkers will likely revolutionize the diagnostic work‐up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer's disease
Y Cheng, CY He, DY Tian, SH Chen, JR Ren… - Acta …, 2023 - Springer
Cerebral amyloid-β (Aβ) accumulation due to impaired Aβ clearance is a pivotal event in the
pathogenesis of Alzheimer's disease (AD). Considerable brain-derived Aβ is cleared via …
pathogenesis of Alzheimer's disease (AD). Considerable brain-derived Aβ is cleared via …
Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective
Sex or gender differences in the risk of Alzheimer's disease and related dementias (ADRD)
differ by world region, suggesting that there are potentially modifiable risk factors for …
differ by world region, suggesting that there are potentially modifiable risk factors for …